SS-31 Protocol: Complete Cycling & Dosing Guide
Overview
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide designed to stabilize the inner mitochondrial membrane by binding to cardiolipin, a phospholipid unique to mitochondrial architecture. Unlike broad-spectrum antioxidants, SS-31 works by preventing cardiolipin peroxidation, preserving electron transport chain function, and reducing reactive oxygen species (ROS) generation at the source—the mitochondria itself.
This makes SS-31 fundamentally different from stimulants or traditional performance compounds. It's a cellular efficiency enhancer that works best for sustained energy, recovery, and conditions involving mitochondrial stress. The peptide shows strong mechanistic benefits across multiple tissue types and modest human clinical evidence for muscle function, injury recovery, and exercise tolerance in disease states.
Critical caveat: SS-31 remains investigational with no FDA-approved indication. Self-administration outside clinical trials carries inherent risks. This guide is educational only and does not replace medical supervision.
Standard Protocol
Dosing Range
The evidence-based dosing window is 0.1–0.5 mg/kg body weight once daily, or a fixed range of 4–40 mg daily via subcutaneous injection.
Practical dosing tiers:
- Low dose: 4–10 mg/day (entry-level, minimal side effects, best for first-timers)
- Standard dose: 10–20 mg/day (most common in clinical protocols, balanced efficacy/tolerability)
- High dose: 20–40 mg/day (used in disease-state trials, increased systemic exposure)
For lean individuals under 150 lbs, dose toward the lower end. For individuals over 200 lbs, dose proportionally higher or use fixed 20–40 mg range.
Cycle Structure
Standard 8-week on / 4-week off cycle:
- Weeks 1–8: Daily injection (same time each day)
- Weeks 9–12: Complete break (allows receptor sensitivity reset and cost management)
- Repeat as needed
For sustained benefits in disease-state populations, trials used 12–28 weeks continuous dosing. For performance/biohacking contexts, the 8/4 split balances efficacy with cost and prevents potential tolerance.
Frequency
SS-31 is dosed once daily via subcutaneous (SQ) injection. A single daily injection maintains steady-state mitochondrial concentration and cardiolipin protection. No divided dosing protocols have been tested; once-daily administration is the standard.
Optimal timing: Early morning (6–9 AM) allows mitochondrial priming for daily energy demands and aligns with natural circadian mitochondrial function peaks.
Reconstitution & Storage
SS-31 is supplied as lyophilized (freeze-dried) powder and requires reconstitution.
Reconstitution steps:
- Calculate total volume needed (concentration typically 10 mg/mL in bacteriostatic water or normal saline)
- Draw bacteriostatic water into syringe
- Inject slowly into vial; allow 2–5 minutes for complete dissolution (do not shake vigorously—swirl gently)
- Once fully dissolved, solution appears clear to slightly opalescent
- Verify clarity; discard if cloudy or particulate
Storage after reconstitution:
- Refrigerated (2–8°C): 14–21 days
- Room temperature (20–25°C): 2–3 days maximum
- Do not freeze reconstituted solution
- Use insulin syringes (28–31 gauge) for injection to minimize injection site reactions
Goal-Specific Protocols
Protocol A: Mitochondrial Recovery & Energy (Standard)
Goal: Enhance ATP production, reduce fatigue, improve sustained work capacity.
Cycle: 8 weeks on, 4 weeks off
Dose: 10–20 mg/day SQ
Target timeline: Effects typically noticed at weeks 2–3 (improved fatigue resistance); peak benefit at weeks 4–6.
Marker of success: Decreased fatigue during aerobic work, improved 6-minute walk test distance (expect 15–30 m improvement if mitochondrial dysfunction present), earlier recovery from training sessions.
Protocol B: Muscle Recovery & Functional Strength (Disease-State Focus)
Goal: Preserve muscle mass during aging or stress; improve muscle mitochondrial function.
Cycle: 10–12 weeks continuous (mimics clinical myopathy trials)
Dose: 20–40 mg/day SQ (higher end to maximize muscle-specific benefits)
Key difference: Extended continuous dosing without off-weeks; clinical evidence for sustained functional improvements (e.g., 6MWT gains) emerged after 8+ weeks of continuous treatment.
Marker of success: Improved work capacity in large muscle groups (squats, deadlifts), reduced exercise-induced soreness, better performance in multi-minute aerobic efforts.
Protocol C: Injury Recovery & Acute Mitochondrial Stress (Peri-Event)
Goal: Mitigate ischemia-reperfusion injury, accelerate tissue repair, reduce post-injury oxidative stress.
Cycle: 2–4 weeks continuous, beginning 3–5 days before planned stressor (surgery, intense training block, hypoxic exposure)
Dose: 20–30 mg/day SQ (higher dose for acute protection)
Timing: Start 3–5 days pre-event, continue 10–14 days post-event for active recovery phase.
Clinical evidence: Phase 2a RCT in renovascular procedures showed elamipretide reduced post-operative hypoxia and increased renal blood flow within 3 months. Dose escalation did not improve outcomes beyond 20–30 mg/day range.
Marker of success: Faster tissue healing markers, reduced systemic inflammation (if CRP measured), improved strength return to baseline, reduced pain/swelling trajectory.
Protocol D: Cognitive Stress & Neuroprotection (Experimental)
Goal: Neuroprotective benefits for mitochondrial-driven cognitive decline; reduces ROS in brain tissue.
Cycle: 12 weeks continuous
Dose: 10–15 mg/day SQ (lower doses adequate for CNS penetration via mitochondrial targeting)
Note: No human RCTs exist for cognition. This protocol is based on strong preclinical evidence (isoflurane cognitive deficits prevented in animals, TBI oxidative stress reversed) but remains experimental.
Marker of success (subjective): Improved mental clarity, sustained focus during cognitively demanding tasks, reduced post-mental-fatigue recovery time.
How to Administer Step-by-Step
Pre-Injection Checklist
- Verify reconstitution status: Solution should be clear, colorless to slightly opalescent. Discard if cloudy.
- Check expiration: Confirm reconstituted solution is within 14–21 days of preparation (refrigerated).
- Inspect for particulates: Hold vial to light; no visible particles.
- Confirm dose: Calculate exact volume needed based on concentration (typically 10 mg/mL).
Injection Technique
- Sanitize: Swab intended injection site with 70% isopropyl alcohol pad; allow 30 seconds to dry.
- Draw: Use insulin syringe (28–31 gauge); draw calculated volume with steady, gentle pressure.
- Air removal: Tap syringe to dislodge air bubbles; expel into waste vial.
- Inject: Insert needle at 45-degree angle into subcutaneous fat (abdomen, thigh, or upper arm). Inject slowly over 5–10 seconds to minimize tissue trauma.
- Withdraw: Remove needle; apply light pressure with alcohol pad for 10–15 seconds.
- Rotate sites: Alternate injection sites daily to reduce localized irritation (abdomen Monday/Thursday, right thigh Tuesday/Friday, left thigh Wednesday/Saturday, upper arm Sunday).
Post-Injection
- Mild erythema or induration at injection site is normal and expected (30–40% of users experience this).
- Apply ice if significant swelling develops (15 minutes, 2–3 times daily).
- Avoid tight clothing over injection site for 2–4 hours.
- Monitor for signs of infection (spreading warmth, pus, fever >101°F) and seek medical attention if present.